Grow Group PLC. The two companies signed a two-year market access services agreement for the U.K.
Previously, the Canadian cannabis giant was one of the first companies to partner with Grow Group in August 2019. Since its original partnership, both companies are said to have dominated the U.K. medical cannabis market. We are delighted to extend our existing strategic relationship with Grow, Miguel Martin, CEO of Aurora Cannabis stated. We have worked successfully with Grow and their joint venture partner, IPS, since entering the UK market.
“Renewing this agreement will help to broaden access for patients by leveraging Grow s work educating physicians and creating awareness of medical cannabis options. Aurora is committed to providing access to legally produced high-quality pharmaceutical-grade medical cannabis to address the needs of the growing European medical cannabis market, made possible with our EU GMP facility, Aurora Nordic,” Martin concluded.
Aurora Cannabis and Grow Group PLC Renew Market Access Services Agreement for Medical Cannabis in the United Kingdom
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Adventist Academy Church Adopts Students, Showering Them with Blessings
adventistworld.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adventistworld.org Daily Mail and Mail on Sunday newspapers.
Press release content from Accesswire. The AP news staff was not involved in its creation.
UK Medicinal Cannabis Company Grow Pharma to Produce Cannabis-Based Medicinal Products for Patients Facing Possible Disruption In Supply
February 2, 2021 GMT
LONDON, ENGLAND / ACCESSWIRE / February 2, 2021 / Innovative UK medicinal cannabis distributor Grow Pharma today announced that they have trialled the first UK extraction of a CBMP in a licensed facility, other than GW Pharmaceuticals, in their efforts to replicate and distribute cannabis-based medicinal products (CBMPs) to patients whose supply may be disrupted due to technicalities relating to Brexit.
“Although it has been announced that a temporary solution has been found and companies are working on a longer term solution which may take months, a post Brexit, sustainable and UK based solution for this problem is needed and we are ready to step up to help,” says Pierre van Weperen, CEO of Grow Pharma. He also mentioned that when